Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 42

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 42
---
 entered a new period focused on strategic pipeline investment, new product launches, efficiency improvements and shareholder returns.

During the three fiscal years ended March 31, 2025, Takeda divested several businesses and assets in non-core areas. See “ Item 5. Operating and Financial Review and Prospects - A. Operating Results” for further details on major businesses and assets acquired and divested.

Our principal capital expenditures during the three fiscal years ended March 31, 2025, comprise our investment in, and acquisition of property, plant and equipment and intangible assets. In the fiscal years ended March 31, 2023, 2024 and 2025, we made capital expenditures (comprising the investment in, and acquisition of property, plant and equipment and intangible assets recorded on our consolidated statements of financial position) of JPY 898.7 billion, JPY 496.7 billion an d JPY319.4 billion r espectively, including the following highlights:

• In the fiscal year ended March 31, 2023, we continued investing in our plasma collection center network, with the addition of 29 new centers to bring Takeda’s total global footprint to 233 centers. We also executed several in-licensing deals and an acquisition to strengthen the pipeline, including zasocitinib (TAK-279) from Nimbus Therapeutics, LLC, fruquintinib from HUTCHMED Limited and TAK-227 from Zedira GmbH and Dr. Falk Pharma GmbH.

• In the fiscal year ended March 31, 2024, we continued investing in our plasma collection center network, with the addition of 27 new centers to bring Takeda’s total global footprint to 260 centers. We also signed a worldwide license and collaboration agreement with Protagonist Therapeutics for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin. In March 2025, the Phase 3 VERIFY trial evaluating rusfertide for the treatement of ploycythemia vera (PV), met its primary endpoint and all key secondary endpoints.

Table of Contents

• In the fiscal year ended March 31, 2025, we continued investing in our plasma donation center network, with the addition of15 new centers to bring Takeda’s total global footprint to 275 centers. We also signed an exclusive licensing agr eement with Keros Therapeutics